{"name":"GNT Pharma","slug":"gnt-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Neu2000KWL group","genericName":"Neu2000KWL group","slug":"neu2000kwl-group","indication":"Acute ischemic stroke","status":"phase_3"}]}],"pipeline":[{"name":"Neu2000KWL group","genericName":"Neu2000KWL group","slug":"neu2000kwl-group","phase":"phase_3","mechanism":"Neu2000KWL is a neuroprotective agent designed to reduce excitotoxic and oxidative damage in the central nervous system.","indications":["Acute ischemic stroke","Traumatic brain injury"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNVktTTE51YVFoV2xoY1hYY1NkazQzYXVnWWFHamNvOV9INFhNZUdWZGlzMjlHZTRuRjZjTEt4c0VFYktSRFBKWmVidDQ4bHdQOEcwcy1lWXlGRG1XZGdYeHl6aUM3cEVHQzZTRjJiWkthQk5ISDZpZW9MWXFCaEdubGJuTFR0WVo4?oc=5","date":"2026-03-02","type":"pipeline","source":"Yahoo Finance","summary":"Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalities Gain Momentum | DelveInsight - Yahoo Finance","headline":"Acute Ischemic Stroke Market Poised for Expansion During the Forecast Period (2026–2036) as Innovative Treatment Modalit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOemd3WFJWN1JZd2sxSjIwWFRXc3oxMWE1ZTdjamdJNmFYY1ZOYXgtSGxUTXY3eVdOUjg3WXpqS0IwbjlQM2lJX0R6ckdGbmNLVUVhOWNDS3NtSXNJZVlSVHpRcnowVm1RVVVOV3ZQem9TZWpyOEJubXM3TmFEV3pkZjhWSWk0dzFPbmd0dlZ5RTRGdHlBU3Byc3RobS1ybFRiZV9hajVpdmRPS1BrUWVR?oc=5","date":"2025-12-22","type":"deal","source":"LinkedIn","summary":"Two of India’s most established pharmaceutical players, Pfizer India & Cipla, have announced their first-ever partnership for the Indian market. Under the strategic tie-up, Cipla will exclusively mark","headline":"Two of India’s most established pharmaceutical players, Pfizer India & Cipla, have announced their first-ever partnershi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOb0tRRFd2RHlfOFc5ZWlVUFlzUjM0d1ZtV2twYVowQTJkSmM5VHlwLWVoYS1GcEd2Zm02cWlaNFF5U1VlNllzY3NiT0ZvYmhrUzFhZDVIRXRwZV9UZ3ltZ0xKUDdVTERteHFuUDcxbUVyXzdLZVR1SFdVeVJKZk9nd21uelpfS3V6b2dOaWd4bmE1LVpUcjN3WnBzS3g5eVh3TjIwczBZd1ZxeXdENjcwTA?oc=5","date":"2025-09-16","type":"pipeline","source":"The Guardian","summary":"Big pharma firms have paused nearly £2bn in UK investments this year | Pharmaceuticals industry - The Guardian","headline":"Big pharma firms have paused nearly £2bn in UK investments this year | Pharmaceuticals industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxQZUVCMnFwcXoyWG40RV8yYnI1NkMtN3UyeUxoRGw4eW5Uckw5NnM1T2t1dkI5VVJPTFg4anhRQUQ4LXBoRnF4SDcxWHM5WjJMTFBwZ05FSVJMdzMtcm5fRlNJQ3Boc3RTVlc5YS04MUFWbnJNQkhZVXlseXZ0YzliRXFiMlc3Ym1EV2dDVDNhX0xtM2IwWXdqdnhidHdqVTNzY0RyTWVNblNpazJEOHl4X0c1T2Z1ZXhaSGJoLXo4ZlZaOVYwOXBRSm80NFkzWThpZWktVXpRanhvYUt5MkE5YXNLNktvbE1zYmt2MUozRDR5Q3k1SFh6M3JMaUc4em41aW1XSWsxcF8xTmhxMGtsRzhJRWUzU0MzUkdZRS1mUjBCNHUzaTIwRV93QWpmOXIxdzVtbE8xOXh2YjB2c3E5bjhn?oc=5","date":"2025-02-19","type":"pipeline","source":"PR Newswire","summary":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Therapies and Breakthroughs by 2034 | DelveInsight - PR Newswire","headline":"Spinal Cord Injury Drug Treatment Market is Predicted to Reach New Heights with the Anticipated Launch of Emerging Thera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5SUUd5NkZ3QzVMM1d6RndRR3lDaVkzZnV1ZzZvR1NuWjhwTzNlcG96YXlxYzFkR01KZ2NMcUl1SG44V0l6U0t3emhSTU01dEl0TElmUFQ4bVY4WG80SXJfZm1tS2cwT18yWGxXcw?oc=5","date":"2024-12-12","type":"trial","source":"팜뉴스","summary":"GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz - 팜뉴스","headline":"GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz - 팜뉴스","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9vM0lGS3BFVEd3TzQyMmJzNmhrMU82OVhyWnVKcmlqaUEwOUtjc2FFTk5uT2s2LVpFSjlMTHAxc2JFZzY0Q1hfaUZIeWkyVWZwY19oUVpn?oc=5","date":"2024-02-05","type":"deal","source":"The Korea Herald","summary":"GNT Pharma partners with Pfizer for animal drug development - The Korea Herald","headline":"GNT Pharma partners with Pfizer for animal drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE14c0FQbHJkRXFXdXpSLXhTb0hxeHRJSFZKeWRuY0ZfdFo5RkxKQ2pRWW13Sl9lQ1pDcWU5aVRyaU8xWkdObTJDSkFJRlh6MzBIX0NGZ3c4OXdyT0tjNXQ2VW95VVFaVjlhRDdIOG1uYw?oc=5","date":"2023-09-05","type":"trial","source":"아시아경제","summary":"GNT Pharma's 'Nellonemdas' Shows Effect in Reducing Cardiac Arrest Brain Damage in Phase 2 Clinical Trial Confirmed - 아시아경제","headline":"GNT Pharma's 'Nellonemdas' Shows Effect in Reducing Cardiac Arrest Brain Damage in Phase 2 Clinical Trial Confirmed - 아시","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOTTdmckxfcW1yaUJZVmdkVFZwM2JQRHJGQ243YjZ2dl9iXzJyaXIwUVJNWExaZmttVFhGWjRxYl9SRGpZdVB6MXdtemx2aVFKYjNzM1Q2Y0NmYWgwUlY1LThWel85Z2NxSjFnTkpFb1hUVG9JdlNlOGRfM2RwLWVpVzRjY2pHbzRhalR5cnBEamlMb0RwY1g2dU9qdWFHYmNDclhhOG9ERF9TdDQ2dm00?oc=5","date":"2023-08-23","type":"patent","source":"PetfoodIndustry","summary":"Company secures patent for pet obesity probiotics - PetfoodIndustry","headline":"Company secures patent for pet obesity probiotics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9XSHVBSFFUektUMXljNVUyc3Rka0FNRG9ieGFQdkRzQ3l2VnVqbXZvVXVGWmZtcFE0ZERnYWtQT2NTMDlZOXh0Szk3NUVmcm94SFFqU29PdnQwYVE4SGFCQTV3MmVjb0NQanFsQjhB0gFyQVVfeXFMTUVIZ2JLMkRuYVhUY0dqRXV6Q1hNb1RaLUNpSnVUSVdIbXZuTktMWkRXcFFCbGhSMzVLRC1UbUdBbnpVYXphMjN4ZWV1czctaEhWU2tVLVA5MHRZdmpMTmhDNlg2SFBMOVQ2di1SWm5sc2tB?oc=5","date":"2023-02-14","type":"pipeline","source":"koreabiomed.com","summary":"GNT Pharma touts Nelonemdaz's efficacy at stroke conference, eyeing 2024 launch - koreabiomed.com","headline":"GNT Pharma touts Nelonemdaz's efficacy at stroke conference, eyeing 2024 launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE8tUFd4SHVWbWVtNnVqQ3psekg1VERhemZzc0psMGdrc0JuMkJIZ0ozYklQY1lKNXY1VHZuOC13R0ljYjlJNHZqZEV0VjV5dmtBc2JjUHJTS0xmMFRHa2Y4c1dtQkNBWEh6U1BNRmxB0gFyQVVfeXFMTy1ENkhadXg0eHg3Slo4VkMyemVDNlZNTlMzT2JwaTItMUxqSFEwdERCWjJSblQyam11UjJWQUlpSTVMc2prMzdhR3JRbDFSc0JhdEZ0NlVocmNDX0R4Zm9rbEpyRTg3LTBlVnRuZnQ2VFNB?oc=5","date":"2021-07-21","type":"pipeline","source":"koreabiomed.com","summary":"Korean drugmakers rush to develop new stroke cure - koreabiomed.com","headline":"Korean drugmakers rush to develop new stroke cure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPR1BMNVI4eWhLZ3ZRaDRwaC1NakRRVkEyaFRHcUpidG5Yamlyc2JCVXpQeVN4ZHVrNkJ4RWUwdllVYWJoV3pRUVd3a2xDS2FwTmhhdVlSb3JYTzNHSmRhSUY1WHV1LWlJSzFwQVBHT09uWTJVN2dYV0pzbFg2MnlpQlNFaF9XUVJlLUNfZ21NMEc3UGR4dnFsZEhrUnhWakNOYldaNXZzX3ZFX0lBNE5GRktpcDVmWDVfWVlmME1ENUNTT01fOGFMQ3ZkRDZVR3RBVzBua1loQm8zdklPb1lkQ1J3?oc=5","date":"2021-02-10","type":"regulatory","source":"Business Wire","summary":"GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome - Business Wire","headline":"GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxQTS1Pa3UxVzI4Zk4zUGEtWFdITHM4d2gyOUNLcTBUZktOY0JBbmFVY3FhZ1hsYW9MVTd6Tk5RU1FpcFhnakZfcDQxaHJSNlUtU3VhZk13Vm9SNzNrd0QwRUxoTzh4Wjd2UVRaNUQxc0NVYmNRUm0za25BV2ppcGk3ZWJfdjYydklKcTNmNW5WMGNvR0tUR0tnQzI3ellNNUlNYmsxVFdtWnpmYjFYUGFiamc2c3NtX3VhbldOWlRXUUdFTkNIdXBhSzdFUFhPejRuMTJ6TXFBcHk3dzI1aUhwYUs0eG9PTUdmTHVOZEJ2bG9aZU5TSFpOZDgxdkJpR2F4ZGR6MFhmaHF0NVg4dTZKUG0wUmw?oc=5","date":"2020-01-14","type":"trial","source":"Business Wire","summary":"GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia - Business Wire","headline":"GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs w","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}